According to the report, an estimated 12.6 million new cases of cancer had been diagnosed in 2008, and 7.6 million people passed away from cancer. The majority of those full cases – 7.1 million and 4.8 million, – occurred in economically developing countries respectively. The spread of an ‘affluence’ disease such as cancer tumor to poorer countries can be attributed to the increasing adoption of harmful behaviors such as for example smoking cigarettes, sedentism and poor diet. The researchers noted that one-third of the cancer tumor deaths in 2008 might have been prevented by simple methods such as for example people quitting smoking, consuming less, consuming better, exercising more and reducing infections risk.The compound is likely to enter stage I trials next 18 months. Dr Keith Blundy, chief executive of CRT, said: ‘This Clinical Development and Choice Agreement is very thrilling for the charity and CRT. The signing of our first deal in the Clinical Advancement Partnership programme demonstrates the way the charity and CRT can work with industry to supply innovative solutions that progress cancer discoveries and medicines towards the patient’. Under the terms of the partnership offer, Cancer Research UK’s highly experienced Drug Development Workplace will conduct the scientific trials free to AstraZeneca. In addition, AstraZeneca retains the choice to assume further advancement and marketing of the drug, with the charity finding a share of any revenues.